, Volume 25, Issue 4, pp 815–824 | Cite as

Synaptic defects associated with s-inclusion body myositis are prevented by copper

  • R. AldunateEmail author
  • A. N. Minniti
  • D. Rebolledo
  • N. C. Inestrosa


Sporadic-inclusion body myositis (s-IBM) is the most common skeletal muscle disorder to afflict the elderly, and is clinically characterized by skeletal muscle degeneration. Its progressive course leads to muscle weakness and wasting, resulting in severe disability. The exact pathogenesis of this disease is unknown and no effective treatment has yet been found. An intriguing aspect of s-IBM is that it shares several molecular abnormalities with Alzheimer’s disease, including the accumulation of amyloid-β-peptide (Aβ). Both disorders affect homeostasis of the cytotoxic fragment Aβ1-42 during aging, but they are clinically distinct diseases. The use of animals that mimic some characteristics of a disease has become important in the search to elucidate the molecular mechanisms underlying the pathogenesis. With the aim of analyzing Aβ-induced pathology and evaluating the consequences of modulating Aβ aggregation, we used Caenorhabditis elegans that express the Aβ human peptide in muscle cells as a model of s-IBM. Previous studies indicate that copper treatment increases the number and size of amyloid deposits in muscle cells, and is able to ameliorate the motility impairments in Aβ transgenic C. elegans. Our recent studies show that neuromuscular synaptic transmission is defective in animals that express the Aβ-peptide and suggest a specific defect at the nicotine acetylcholine receptors level. Biochemical analyses show that copper treatment increases the number of amyloid deposits but decreases Aβ-oligomers. Copper treatment improves motility, synaptic structure and function. Our results suggest that Aβ-oligomers are the toxic Aβ species that trigger neuromuscular junction dysfunction.


Inclusion body myositis Amyloid-β-peptide Copper C. elegans Neuromuscular junction 



We thank Paula Grez, for her contribution to Fig. 1 of this work, and Dr. William Klunk for providing the X-34 dye. We are grateful to Dr. Chris Link for his generous gift of C. elegans strains. Some strains were provided by the Caenorhabditis Genetics Center (CGC). Financial support: Grant 13980001, Centro de Envejecimiento y Regeneración (CARE), Programa de Financiamiento Basal 12/2007. FONDECYT 1120213 to RA.

Supplementary material

Supplementary material 1 (MP4 1120 kb)

Supplementary material 2 (MP4 178 kb)

Supplementary material 3 (MP4 405 kb)


  1. Adams RD, Kakulas BA, Samaha FA (1965) A myopathy with cellular inclusions. Trans Am Neurol Assoc 90:213–216PubMedGoogle Scholar
  2. Askanas V, Engel WK (2001) Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 60:1–14PubMedGoogle Scholar
  3. Askanas V, Engel WK (2002) Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms. Curr Opin Neurol 15:525–531PubMedCrossRefGoogle Scholar
  4. Askanas V, Engel WK (2006) Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 66:S39–S48PubMedCrossRefGoogle Scholar
  5. Askanas V, Engel WK (2007) Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 19:550–559PubMedCrossRefGoogle Scholar
  6. Askanas V, Engel WK (2008) Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer’s and Parkinson’s disease brains. Acta Neuropathol 116:583–595PubMedCrossRefGoogle Scholar
  7. Askanas V, Alvarez RB, Engel WK (1993) Beta-amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 34:551–560PubMedCrossRefGoogle Scholar
  8. Bayer TA, Schafer S, Simons A, Kemmling A, Kamer T, Tepest R, Eckert A, Schussel K, Eikenberg O, Sturchler-Pierrat C, Abramowski D, Staufenbiel M, Multhaup G (2003) Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci USA 100:14187–14192PubMedCrossRefGoogle Scholar
  9. Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J (2004) Copper depletion down-regulates expression of the Alzheimer’s disease amyloid-beta precursor protein gene. J Biol Chem 279:20378–20386PubMedCrossRefGoogle Scholar
  10. Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77:71–94PubMedGoogle Scholar
  11. Buckingham SD, Jones AK, Brown LA, Sattelle DB (2009) Nicotinic acetylcholine receptor signalling: roles in Alzheimer’s disease and amyloid neuroprotection. Pharmacol Rev 61:39–61PubMedCrossRefGoogle Scholar
  12. Bush AI, Pettingell WH Jr, Paradis MD, Tanzi RE (1994a) Modulation of A beta adhesiveness and secretase site cleavage by zinc. J Biol Chem 269:12152–12158PubMedGoogle Scholar
  13. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE (1994b) Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265:1464–1467PubMedCrossRefGoogle Scholar
  14. Bush AI, Masters CL, Tanzi RE (2003) Copper, beta-amyloid, and Alzheimer’s disease: tapping a sensitive connection. Proc Natl Acad Sci USA 100:11193–11194PubMedCrossRefGoogle Scholar
  15. Cerpa WF, Barria MI, Chacon MA, Suazo M, Gonzalez M, Opazo C, Bush AI, Inestrosa NC (2004) The N-terminal copper-binding domain of the amyloid precursor protein protects against Cu2+ neurotoxicity in vivo. FASEB J 18:1701–1703PubMedGoogle Scholar
  16. Cerpa W, Varela-Nallar L, Reyes AE, Minniti AN, Inestrosa NC (2005) Is there a role for copper in neurodegenerative diseases? Mol Aspects Med 26:405–420PubMedCrossRefGoogle Scholar
  17. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 30:665–676PubMedCrossRefGoogle Scholar
  18. D’Andrea MR, Nagele RG (2006) Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer’s disease pyramidal neurons. Curr Pharm Des 12:677–684PubMedCrossRefGoogle Scholar
  19. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-Methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590–11601PubMedCrossRefGoogle Scholar
  20. Dineley KT, Bell KA, Bui D, Sweatt JD (2002) Beta-amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 277:25056–25061PubMedCrossRefGoogle Scholar
  21. Fay DS, Fluet A, Johnson CJ, Link CD (1998) In vivo aggregation of beta-amyloid peptide variants. J Neurochem 71:1616–1625PubMedCrossRefGoogle Scholar
  22. Francis MM, Evans SP, Jensen M, Madsen DM, Mancuso J, Norman KR, Maricq AV (2005) The Ror receptor tyrosine kinase CAM-1 is required for ACR-16-mediated synaptic transmission at the C. elegans neuromuscular junction. Neuron 46:581–594PubMedCrossRefGoogle Scholar
  23. Harrington AJ, Knight AL, Caldwell GA, Caldwell KA (2011) Caenorhabditis elegans as a model system for identifying effectors of alpha-synuclein misfolding and dopaminergic cell death associated with Parkinson’s disease. Methods 53:220–225PubMedCrossRefGoogle Scholar
  24. Inestrosa NC, Cerpa W, Varela-Nallar L (2005) Copper brain homeostasis: role of amyloid precursor protein and prion protein. IUBMB Life 57:645–650PubMedCrossRefGoogle Scholar
  25. Kessler H, Pajonk FG, Supprian T, Falkai P, Multhaup G, Bayer TA (2005) The role of copper in the pathophysiology of Alzheimer’s disease. Nervenarzt 76:581–585PubMedCrossRefGoogle Scholar
  26. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci 27:796–807PubMedCrossRefGoogle Scholar
  27. LaFerla FM, Oddo S (2005) Alzheimer’s disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 11:170–176PubMedCrossRefGoogle Scholar
  28. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 8:499–509PubMedCrossRefGoogle Scholar
  29. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352–357PubMedCrossRefGoogle Scholar
  30. Link CD (1995) Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 92:9368–9372PubMedCrossRefGoogle Scholar
  31. Link CD (2005) Invertebrate models of Alzheimer’s disease. Genes Brain Behav 4:147–156PubMedCrossRefGoogle Scholar
  32. Link CD, Johnson CJ, Fonte V, Paupard M, Hall DH, Styren S, Mathis CA, Klunk WE (2001) Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging 22:217–226PubMedCrossRefGoogle Scholar
  33. Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ (1989) Inclusion body myositis. Observations in 40 patients. Brain 112(Pt 3):727–747PubMedCrossRefGoogle Scholar
  34. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, Morris JC (2001a) Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease. Neurology 56:127–129PubMedCrossRefGoogle Scholar
  35. Masliah E, Alford M, Galasko D, Salmon D, Hansen LA, Good PF, Perl DP, Thal L (2001b) Cholinergic deficits in the brains of patients with parkinsonism-dementia complex of Guam. Neuroreport 12:3901–3903PubMedCrossRefGoogle Scholar
  36. McColl G, Roberts BR, Gunn AP, Perez KA, Tew DJ, Masters CL, Barnham KJ, Cherny RA, Bush AI (2009) The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. J Biol Chem 284:22697–22702PubMedCrossRefGoogle Scholar
  37. McFerrin J, Engel WK, Askanas V (1998) Impaired innervation of cultured human muscle overexpressing betaAPP experimentally and genetically: relevance to inclusion-body myopathies. Neuroreport 9:3201–3205PubMedCrossRefGoogle Scholar
  38. Miller KG, Alfonso A, Nguyen M, Crowell JA, Johnson CD, Rand JB (1996) A genetic selection for Caenorhabditis elegans synaptic transmission mutants. Proc Natl Acad Sci USA 93:12593–12598PubMedCrossRefGoogle Scholar
  39. Minniti AN, Rebolledo DL, Grez PM, Fadic R, Aldunate R, Volitakis I, Cherny RA, Opazo C, Masters C, Bush AI, Inestrosa NC (2009) Intracellular amyloid formation in muscle cells of Abeta-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification. Mol Neurodegener 4:2PubMedCrossRefGoogle Scholar
  40. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050–4058PubMedGoogle Scholar
  41. Nagele RG, D’Andrea MR, Anderson WJ, Wang HY (2002) Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience 110:199–211PubMedCrossRefGoogle Scholar
  42. Perry EK, Perry RH, Smith CJ, Dick DJ, Candy JM, Edwardson JA, Fairbairn A, Blessed G (1987) Nicotinic receptor abnormalities in Alzheimer’s and Parkinson’s diseases. J Neurol Neurosurg Psychiatry 50:806–809PubMedCrossRefGoogle Scholar
  43. Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG, Irving D, Brown A, Perry RH (1995) Alteration in nicotine binding sites in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease: possible index of early neuropathology. Neuroscience 64:385–395PubMedCrossRefGoogle Scholar
  44. Rebolledo DL, Minniti AN, Grez PM, Fadic R, Kohn R, Inestrosa NC (2008) Inclusion body myositis: a view from the Caenorhabditis elegans muscle. Mol Neurobiol 38:178–198PubMedCrossRefGoogle Scholar
  45. Rebolledo DL, Aldunate R, Kohn R, Neira I, Minniti AN, Inestrosa NC (2011) Copper reduces Abeta oligomeric species and ameliorates neuromuscular synaptic defects in a C. elegans model of inclusion body myositis. J Neurosci 31:10149–10158PubMedCrossRefGoogle Scholar
  46. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685–1691PubMedCrossRefGoogle Scholar
  47. Sattelle DB, Buckingham SD (2006) Invertebrate studies and their ongoing contributions to neuroscience. Invert Neurosci 6:1–3PubMedCrossRefGoogle Scholar
  48. Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298:789–791PubMedCrossRefGoogle Scholar
  49. Strausak D, Mercer JF, Dieter HH, Stremmel W, Multhaup G (2001) Copper in disorders with neurological symptoms: Alzheimer’s, Menkes, and Wilson diseases. Brain Res Bull 55:175–185PubMedCrossRefGoogle Scholar
  50. Toledo EM, Inestrosa NC (2009) Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer’s disease. Mol Psychiatry 15:272–285, 228Google Scholar
  51. Wang HY, Lee DH, Davis CB, Shank RP (2000a) Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 75:1155–1161PubMedCrossRefGoogle Scholar
  52. Wang HY, Lee DH, D’Andrea MR, Peterson PA, Shank RP, Reitz AB (2000b) Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology. J Biol Chem 275:5626–5632PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • R. Aldunate
    • 1
    • 2
    Email author
  • A. N. Minniti
    • 1
  • D. Rebolledo
    • 1
  • N. C. Inestrosa
    • 1
  1. 1.Center for Aging and Regeneration (CARE), Facultad de Ciencias BiológicasPontificia Universidad Católica de ChileSantiagoChile
  2. 2.Escuela de Biotecnología, Facultad de CienciasUniversidad Santo TomásSantiagoChile

Personalised recommendations